reports
- GlobalData Healthcare Department
BerGenBio ASA - Company Review
BerGenBio ASA - Company Review Summary BerGenBio ASA (BerGenBio) is a developer of drugs for aggressive and drug resistant cancers. The company develops epithelial-mesenchymal transition inhibitors for acquired cancer drug-resistance and metastasis. Its BGB324 finds application in the treatment of drug resistant chronic myeloid leukemia. BerGenBio’s cellselect is a drug discovery and validation technology that identifies and validates novel drug targets and biomarkers. The company’s cellse...
Unfortunately, this report is not available for the investor type or country you selected.
Report is subscription only.
Thank you, your report is ready.
Thank you, your report is ready.